Compare · KRRO vs LLY
KRRO vs LLY
Side-by-side comparison of Korro Bio Inc. (KRRO) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRRO and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 6285.0x KRRO ($176.7M).
- KRRO has been more active in the news (6 items in the past 4 weeks vs 5 for LLY).
- Both have 25 recent analyst ratings on file.
- Company
- Korro Bio Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $176.7M
- $1.11T
- 1M return
- +15.23%
- -
- 1Y return
- -7.54%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 6
- 5
- Recent ratings
- 25
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest KRRO
- Chief Scientific Officer Vincent Loic A was granted 7,500 shares, increasing direct ownership by 41% to 25,797 units (SEC Form 4)
- Senior Vice President, Finance Dolan Oliver was granted 5,500 shares, increasing direct ownership by 30% to 23,599 units (SEC Form 4)
- General Counsel Cerio Jeffrey was granted 6,500 shares, increasing direct ownership by 18% to 41,793 units (SEC Form 4)
- Chief Operating Officer Chappell Todd was granted 7,500 shares, increasing direct ownership by 44% to 24,464 units (SEC Form 4)
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Formela Jean Francois sold $1,542,970 worth of shares (110,023 units at $14.02) as part of a pre-agreed trading plan (SEC Form 4)
- Director Formela Jean Francois sold $2,458,582 worth of shares (171,405 units at $14.34) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Chappell Todd sold $34,309 worth of shares (3,168 units at $10.83), decreasing direct ownership by 16% to 16,964 units (SEC Form 4) to satisfy withholding tax
- Chief Scientific Officer Vincent Loic A sold $37,017 worth of shares (3,418 units at $10.83), decreasing direct ownership by 16% to 18,297 units (SEC Form 4) (withholding obligation)
- General Counsel Cerio Jeffrey sold $71,575 worth of shares (6,609 units at $10.83), decreasing direct ownership by 16% to 35,293 units (SEC Form 4) (tax liability)
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend